The Latest in CLL

Telomere length predicts FCR response in CLL patients

July 5, 2017

CLL

Optimizing therapy in relapsed CLL: ibrutinib and beyond

June 23, 2017

CLL

Twofer drug blocks SYK/JAK pathways in advanced NHL

June 23, 2017

FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLL

June 22, 2017

Lenalidomide consolidation linked to extended overall survival in non-del(11q) CLL

June 22, 2017

CLL

Sequential triple therapy produces high response rates in CLL

June 21, 2017

CLL

Hitting BTK, PI3K pays off in B-cell malignancies

June 20, 2017

NOTCH1 mutation predicts reduced ofatumumab efficacy in CLL

June 5, 2017

CLL

iFCG achieves high MRD-negative remission in untreated CLL

May 30, 2017

CLL

ECG finding predicts AFib in ibrutinib-treated CLL

May 23, 2017

CLL

In good-candidate CLL, don’t wait too long for alloHCT

May 22, 2017

CLL

Ibrutinib response in CLL/SLL less affected by select risk factors

May 21, 2017

CLL

Targeted drugs transform CLL management

April 24, 2017

CLL

Venetoclax produces durable effects in relapsed/refractory CLL

March 29, 2017

CLL

Advanced CLL treatment approach depends on comorbidity burden

March 27, 2017

CLL